AXS-14 (Esreboxetine)

Drug identity checked against registry records

Also recorded as AXS-14; Esreboxetine

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research DesignNCT07398417AXSMPhase 3Recruiting2028-03Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.